Las Vegas, September 1, 2021 (PRNewswire) – Alkame Holdings, Inc. $ 100,000 In Proposeory Notes.
Blue City LLC has agreed to set up its own structure $ 100,000, 12% interest rate immediately converted to Alcame Holdings joint stock $ 0.01 In one share. This is the first step in the company’s efforts to secure a revolving credit line to support joint venture growth by the end of this year and by 2022.
Although the first half of the year is challenging as we work to complete our move to a new production facility during the epidemic, we are already seeing high demand and, in addition, production needs. Our new facility allows us to move forward. As a company that responds to customer needs and handles the complexities of our many co-packing operations, we look forward to increasing our production capacity to accelerate our processes as we increase our production capacity for 2022. ” Robert Eckle“As we have pointed out, our reform efforts are aimed at strengthening our production capacity and financial capacity in the future,” said Alcame CEO.
About Alkame Holdings, Inc.
Alcame Holdings is an publicly traded health and safety technology company focused on inpatient, innovative and environmentally friendly consumer products. The company’s full-fledged branches produce patented water using patented technology to create a number of unique properties. The company has launched and acquired appropriate business assets, and followed a number of applications into a number of emerging business sectors such as consumer bottled water and RTD products, pet products, horticultural and agricultural applications, hand sanitizers for new and existing business platforms and much more. Water-based treatment solutions.
For more information, visit www.alkameholdingsinc.com.
Alkame Holdings, Investor Relations
Email: [email protected]
Disclaimer / Safe Harbor: This newsletter contains forward-looking statements in the translation of the Safe Arbitration Amendment Act. The statements reflect the company’s current views on future events, including risks and mistrust. Among other risks, these risks include significant sales, failure to meet the company’s contract timetable or performance requirements, the company’s liquidity, the company’s ability to obtain new contracts, the emergence of highly competitive competitors, and the impact of competitive prices. In light of these instability, future events mentioned in this release may not occur. These statements have not been reviewed by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.
Source: Alkame Holdings, Inc.